<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384186</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-011</org_study_id>
    <secondary_id>2017-003525-15</secondary_id>
    <nct_id>NCT03384186</nct_id>
  </id_info>
  <brief_title>A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Pharmacokinetic Profile of ACH-0144471 Following Administration of Modified Release Prototype Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate and compare the plasma pharmacokinetic profiles of&#xD;
      ACH-0144471 (danicopan) in healthy participants after administration of single oral doses of&#xD;
      modified release prototype formulations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">March 21, 2018</completion_date>
  <primary_completion_date type="Actual">March 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time To Maximum Observed Concentration (Tmax) Of Danicopan After Treatment With Each Prototype Formulation</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) Of Danicopan After Treatment With Each Prototype Formulation</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Danicopan After Treatment With Each Prototype Formulation</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants Experiencing Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 (postdose) through follow-up visit (10 [+/- 2] days after last study drug administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Danicopan Modified Release Prototype Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received danicopan once each period as a single oral dose as follows:&#xD;
Period 1: Danicopan Modified Release Prototype 1 under fasted conditions. Period 2: Danicopan Modified Release Prototype 2 under fasted conditions. Period 3: Danicopan Modified Release Prototype 3 under fasted conditions. Period 4: Danicopan Modified Release Prototype 2 under fed conditions.&#xD;
There was a washout period of at least 14 days between each danicopan dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan Modified Release Prototype 1</intervention_name>
    <description>Danicopan (400 milligrams [mg]) oral tablet.</description>
    <arm_group_label>Danicopan Modified Release Prototype Tablets</arm_group_label>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-0144471 (formerly)</other_name>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan Modified Release Prototype 2</intervention_name>
    <description>Danicopan (400 mg) oral tablet.</description>
    <arm_group_label>Danicopan Modified Release Prototype Tablets</arm_group_label>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-0144471 (formerly)</other_name>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan Modified Release Prototype 3</intervention_name>
    <description>Danicopan (800 mg) oral tablet.</description>
    <arm_group_label>Danicopan Modified Release Prototype Tablets</arm_group_label>
    <other_name>ALXN2040</other_name>
    <other_name>ACH-0144471 (formerly)</other_name>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index of 18.0 to 30.0 kilograms/square meter.&#xD;
&#xD;
          -  Female participants of childbearing potential must either agree to abstinence or use&#xD;
             of a highly effective method of contraception.&#xD;
&#xD;
          -  Male participants must either agree to abstinence or use of a condom plus an effective&#xD;
             method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have received any investigational medicinal product in a clinical&#xD;
             research study within the previous 3 months.&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years; current tobacco/nicotine&#xD;
             user or within the last 12 months; positive drugs of abuse test result.&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities.&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, chronic respiratory&#xD;
             or gastrointestinal disease, neurological or psychiatric disorder.&#xD;
&#xD;
          -  History or family history of meningococcal infection.&#xD;
&#xD;
          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients.&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment.&#xD;
&#xD;
          -  Donation or loss of greater than 400 milliliters of blood within the previous 3&#xD;
             months.&#xD;
&#xD;
        Note: Other inclusion/exclusion criteria may apply, per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG111 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Danicopan</keyword>
  <keyword>ALXN2040</keyword>
  <keyword>ACH-0144471</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Modified Release</keyword>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Relative Bioavailability</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

